UK-headquartered drug giant GlaxoSmithKline is building a S$50 million($29.2 million) drug technology center that will double the firm's laboratory space in Singapore, reports the local Business Times. The announcement came during the opening of a new S$100 million extension at GSK's Jurong site, it was noted, and the new project will bring the group's total investment in Singapore to S$1 billion. The newly-completed site will manufacture the firm's asthma drug fluticasone propionate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze